Federal contract opportunity NOI-RML6-14004 for research and development in the physical, engineering, and life sciences (except biotechnology) at National Institutes of Health National Institute of Allergy & Infectious Diseases/AMOB, response was due Jan 17, 2014.

Synopses View


The Government intends to negotiate on a sole source basis with National Institute for Research in Tuberculosis to provide Field Support Services in accordance with the format in Subpart 12.6, as applicable, and supplemented with additional information included in this notice.   This announcement constitutes the only solicitation; quotes are not being requested and a written solicitation will not be issued.  The solicitation number for this acquisition is NOI-RML6-14004 and the solicitation is being issued as a Notice of Intent on a sole source basis.


 


(ii) The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-72 dated Jan 1st, 2014.  This acquisition will be processed under Simplified Acquisition Procedures (SAP) and is not a Small Business Set-Aside. The North American Industry Classification System (NAICS) code for this procurement is 541712 and the small business size is 500.  


The purpose of this acquisition is to allow the development of a monoclonal-based antigen capture assay specific to T. solium taenia( tapeworm). The methodology is straight forward and uses techniques and reagents that are available or producible.  Monoclonal antibodies (Mab) will be produced in mice to excretory-secretory antigens of T.solium tapeworms by harvesting and culturing in vitro developing tapeworms grown in immunosuppressed hamsters. Mice will be immunized per protocol, the immune sera tested for reactivity and Mabs produced by standard techniques. Clones will be screened by a standard ELISA assay for reactive clones employing E-S products to T. solium tapeworms. Positive clones will then be recloned and Mabs tested in various formats for use in taenia antigen capture assays. There is a well-defined set of feces (T. solium or T. saginata infected, nematode infected, other tapeworm infected or not infected), that has previously been used to determine sensitivity and specifity for the above-mentioned assay that can be used in testing for this project.


Because the life cycle of T. solium and various stages are not present in the U.S., by necessity experiments need to be performed in endemic regions such as in Peru. Universidad Peruana Cayetano Heredia is a supported research laboratory in Lima, Peru, that is devoted to the study of T. solium. This laboratory has access to all stages of the parasite. This will allow continued support for collaborative research between NIH and the Universidad Peruana Cayetano Heredia, Lima, Peru and specifically this will allow development of a test to specifically diagnose T. solium tapeworm carriers, which could lead to elimination of this disease.


a. The vendor shall provide



  1. Monoclonal antibodies( MAb)to T. solium specific tapeworm antigens

  2. Working T. solium detection assay that is both sensitive and specific to T. solium

  3. Evaluation, selection, preparation, treatment, and follow-up of patients under study

  4. Development of tests and studies to lead to a better understanding and treatment of human diseases


 


b. Vendor requirements:


 



  1. The vendor must have a research publication record specific for Taenia solium, development of Mabs and tests specific to T. solium.

  2. Evaluate, select, prepare Mab to T. solium specific antigens

  3. Have ready access to T. solium tapeworms

  4. Availability of T. solium tapeworm infected carries to determine sensitivity of the various Mabs

  5. Availability of T. saginata infected patients to determine specificity of the Mabs

  6. Ability to produce T. solium tapeworm in hamsters

  7. Have T. solium cyst available to infect hamsters

  8. At least person in the vendor organization must have a medical degree and post graduate training and certification in infectious diseases and research experience and understanding of the organism Taenia solium.

  9. The vendor must be proficient in producing monoclonal antibodies against Taenia solium and in their evaluation against the cyst form and drug treated cysts.

  10. The vendor must have the ability to manipulate, culture, and work with the parasite, Taenia solium.

  11. The vendor must be able to start research within two weeks on Taenia solium.


FOB Point shall be Destination, Bethesda, MD. Delivery location is National Institute of Health, Bethesda, MD 20892.  The following FAR provisions and clauses apply to this acquisition: 52.212-1 Instructions to Offerors—Commercial Items (July 2013); FAR 52-212-4 Contract Terms and Conditions—Commercial Items (Nov 2013); FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders(Nov 2013)—Commercial Items The following are clauses applicable to this acquisition incorporated by reference 52.219-4, 52.222-3,  52.222-19, 52.222-21, 52.222-26, 52.225-13, 52.232-33, 52.222-41; FAR 52.212-3 Offerors Representations and Certifications—Commercial Items. In order to be considered for an award, offeror must have completed the Online Representations and Certifications located at http://www.sam.gov/ in accordance with FAR 4.1201(a). By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the SAM database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation.



Offers may be emailed to michael.barrett@nih.gov, at 903 South 4th Street Hamilton, MT 59840, mailed or faxed to the POC indicated above (Fax - 406-363-9288).  Offers must be submitted not later than 4:30 PM (MDST) 1/17/2014. Copies of the above-referenced clauses are available from http://www.acquisition.gov/far/loadmainre.html or upon request, either by telephone or fax.  All responsible sources may submit an offer that will be considered by this Agency. 


Place of Performance